Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

[News]

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

More... (http://www.news-medical.net/news/20091207/Dabigatran-etexilate-prevents-recurrent-VTE-with-less-bleeding-than-warfarin.aspx)